Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xolair in Urticaria Factitia (UFO)
NCT02169115Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Dec 2012
- Primary completion
- Dec 2014
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of omalizumab in dermatographism, sponsored by Charité – Universitätsmedizin Berlin. Started Dec 2012; status: completed.
02
Drugs
omalizumab
03
Conditions
dermatographism
Beyond the preview
Go deeper on NCT02169115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02169115.